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Plasma tumor necrosis factor soluble receptors in chronic renal failure.
Two soluble tumor necrosis factor receptors (sTNFRs) were detected in
the plasma of patients with different degrees of chronic renal failure
(CRF) and of long-term hemodialysis (HD) patients. In uremic undia-
lyzed patients, plasma levels of both sTNFRs increased progressively
with declining renal function. A linear correlation was found between
sTNFR plasma levels and plasma creatinine concentration. sTNFR
levels in end-stage uremic patients shortly before commencement of
first HD treatment were approximately tenfold higher than in normal
subjects. Long-term HD patients showed a further increase in plasma
sTNFRs. The origin of sTNFRs, as well as their physiological role
remains to be elucidated.
Tumor necrosis factor-a (TNFa) is produced primarily by
monocytes/macrophages, and participates in a wide range of
biological activities. It is an important mediator of various host
responses to acute or chronic injury, infection and neoplasia
[1—3]. When TNFa is produced in limited amounts it may have
a beneficial role in controlling the outcome of infections, as well
as in modulating the metabolic activities of diverse tissues
[4—9]. However, when excessively produced, as in septic
shock, it can lead to host mortality [10—15].
Recently, TNF binding proteins (TNFBP) were purified from
urine [16—20] and from HL-60 cell lysates [21], and were
identified as soluble receptors (sTNFRs) of TNF [2 1—24]. sTN-
FRs bind TNF with high affinity and high specificity, thereby
blocking the different biological activities induced by TNF in
vitro [24, 25]. Recently, it has been shown that sTNFRs also
confer some TNF-antagonizing effects in vivo: they have been
reported to protect mice from LPS-induced mortality [26] and
to prevent, in BALB/c mice, TNF-induced hemorrhagic necro-
sis of a transplanted Meth-A sarcoma [27].
Hemodialysis (HD) treatment is associated with activation of
mononuclear cells [28—311. Such activation can stimulate mono-
nuclear cells to produce cytokines [32]. Increased transcription
of mRNA coding for TNFa, without translation, occurs in
mononuclear cells during HD [33]. Contradictory observations
have been reported with regard to levels of TNFa in the plasma
of HD patients. Levels of TNFa before the start of HD sessions
were either normal [34] or elevated [35], while HD treatment
appeared either to induce an increase [34] or to have no
influence [35] on plasma TNFa levels. We have recently shown,
however, that high levels of TNFBP present in the plasma and
urine of HD patients interfere with the determination of TNFa
by immunoassays [36].
Although particularly high levels of sTNFRs were reported in
plasma and urine of hemodialysis patients [17], the actual levels
have not been reported. In the present study we employed a
specific and sensitive immunoassay for measurement of the
concentrations of two sTNFRs in the plasma and urine of
uremic patients. We also attempted to determine the extent to
which these levels are affected by uremia and hemodialysis.
Methods
Subjects
Included in the study were 25 patients (18 men and 7 women)
with chronic renal failure (CRF). Their ages ranged from 29 to
75 years (mean 48.6 years). Of these 15 were long-term hemo-
dialysis (HD) patients, receiving between 4 to 13 years (mean
6.6 years) of HD treatment for four hours, three times a week.
All of them except one were anuric patients. HD was performed
using cuprophane membranes. The other 10 patients had vari-
ous degrees of renal failure, with plasma creatinine concentra-
tions ranging from 0.19 to 0.8 mM/liter. Four of these patients
were in the end-stage of renal failure (ESRD) and started
dialysis treatment within a month of the study. The age-
matched healthy controls (mean 46.0, ranged from 30 to 70
years) included two men and three women.
Samples
Heparinized blood (10 U/mi) was withdrawn from each
subject. The blood samples were taken from the antecubital
vein of control subjects and undialyzed CRF patients, while in
HD patients they were taken from the arteriovenous fistula
immediately before starting and at the end of dialysis session.
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TNFa measurement
TNFa was determined by using the T-Cell-Sciences ELISA
kit. The assay is a "sandwich" immunoassay employing two
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different monoclonal anti-TNFa antibodies. The assay detects
biologically active TNFa only, with a sensitivity of 10 pg/mi.
sTNFRs measurement
The assay is a slight modification of a procedure already
published [37, 381. The assay is based on a sandwich between
monoclonal antibodies raised against TNFR-A(p75) or TNFR-
B(p55) and 1251-TNF. Polyvinyl plates (96 well, Dynatech
Alexandria, Virginia, USA) were first coated with affinity-
purified rabbit-anti-mouse IgG (10 tg/m1 in PBS, 50 id/well), to
increase attachment of the monoclonal antibody to the plastic.
The sensitized plates were incubated overnight at 4°C with a
solution of mouse monoclonal antibody to either TNFR-A(p75)
or TNFR-B(p55), (10 .tg/ml) in blocking buffer [Tris-Hcl (50
mM) pH 7.4, NaCI (140 mM), EDTA (5 mM), de-lipidated milk
powder (1%)]. The monoclonal antibody utr-4 for TNFR-A(p75)
and htr-20 against TNFR-B(p55) are specific, noncrossreactive
and directed to non-inhibitory epitopes of the respective
TNFRs [39, 40]. The wells were washed once with PBS. Urine
and plasma samples were diluted 1:20 in blocking buffer before
being added to the plates in aliquots of 45 id/well. The plates
were incubated for 14 hours at 4°C and washed once with PBS.
'251TNF (450 Ci/mmol, 106 cpmlml) in blocking buffer, was
then added to 50 p1/well aliquots. Plates were incubated for two
hours at 4°C, and washed four times with PBS. The bound
radioactivity was measured in each well by gamma scintillation
counting. Nonspecific binding of '251-TNF was determined in
the absence of serum and was less than 5% of the total counts.
The data was corrected for nonspecific binding. The specific
binding of '251-TNF to sTNFRs could be prevented either by
the addition of 20 ,tsg/ml of unlabeled TNFa, or by replacing the
anti-TNFR monoclonal antibodies by nonspecific antibodies,
thus confirming the specificity of the assay. Linearity of the
assay was verified using TNFRs from cell lysate of HL6O cells
[21], as well as recombinant TNFR-A(p75) and TNFR-B(p55)
[25, 41]. The concentration of sTNFR-B(p55) was calculated
from the amount of bound radioactivity using a 1:1 binding
stoichiometry between '251-TNF and sTNFR-B(p55) [25]. The
concentrations calculated this way were consistent with those
obtained by using recombinant sTNFR-B(p55) as the standard.
We assumed the same stoichiometry for the calculation of the
concentration of sTNFR-A(p75) as well. Results are expressed
as ng/ml, assuming a molecular weight of 30 kDa for both
sTNFRs.
Post-HD levels were corrected for ultrafiltration using weight
changes, according to Bergstrom and Wehie [42].
Statistical analysis
All data were expressed as means SD. Data were analyzed
using the Student's t-test (paired or unpaired). A probability of
less than 0.05 was considered as significant.
Results
Plasma sTNFR levels
Figure 1 compares the concentrations of the two types of
sTNFRs detected in the plasma of 13 long-term HD patients,
four ESRD patients shortly before the initiation of HD treat-
ment (mean plasma creatinine 0.69 0.09 mM/liter, range 0.6 to
0.8 mM/liter), and of five normal subjects. All HD patients were
Normal ESRD ESRD-i-HD
Fig. 1. Plasma immunoreactive levels of sTNFR-A(p75, ) and
sTNFR -B (p55, 0) in normal controls (N = 5), undialyzed patients with
end-stage renal disease (ESRD) (creatinine range 0.6 to 0.8 mM/liter)(N = 4) and ESRD patients after long-term hemodialysis (HD) (N
13). Results are means SD.
tested immediately before a dialysis session was started. The
mean concentrations of sTNFRs in the plasma of both groups of
ESRD patients were considerably higher than that of the normal
subjects [sTNFR-A(p75), 2.36 ng/ml 0.8; sTNFR-B(p55),
2.68 ng/ml 0.94]. Among the patients with ESRD, mean
plasma sTNFR levels in the long-term HD group [sTNFR-
A(p75), 29.6 ng/ml 9.5; 5TNFR-B(p55), 55.27 ng/ml 11.95]
were significantly higher (P < 0.001) than in the undialyzed
group [sTNFR-A(p75), 19.57 ng/ml 7.5; sTNFR-B(p55), 27.0
ng/ml 7.7]. Moreover, as shown in Figure 1, in each of these
groups there was a marked difference in the level between the
two types of receptors: in HD patients the mean level of
sTNFR-B(p55) in the plasma was approximately twice as high
as that of sTNFR-A(p75) (P < 0.001), while in the undialyzed
ESRD group the difference, though less pronounced, was still
significant (P < 0.01). In contrast, no significant difference was
observed between the levels of the two types of sTNFR in
normal subjects.
Relationship between renal failure and sTNFR levels
To establish the relationship between renal failure and circu-
lating levels of sTNFRs, plasma sTNFR levels were determined
in 10 undialyzed patients with different degrees of CRF. Plasma
creatinine levels in these patients ranged from 0.19 to 0.8
mM/liter. The levels of sTNFRs in the plasma were found to
increase with decreasing renal function. A strong linear corre-
lation between plasma levels of sTNFR-A(p75) or sTNFR-
B(p55) and plasma creätinine or urea concentrations was ob-
served (Fig. 2). Also, in these patients plasma sTNFR-B levels
were consistently higher than those of sTNFR-A (P < 0.01). No
such correlations between plasma sTNFR levels and plasma
creatinine or urea were obtained in HD patients, as shown in
Figure 3.
Effect of a dialysis session
In nearly all of the patients the plasma levels of both sTNFR
were higher at the end of a dialysis session than before it was
started. Analysis of the data revealed that the increment (13.9%
7.2) induced by HD treatment was significant (P < 0.01) and
correlated with weight loss occurring during a dialysis session



















Fig. 2. Correlation between plasma
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Since urine (from normal, febrile, or HD patients) is the
source from which TNF binding proteins were first isolated, we
measured the concentrations of sTNFRs in the urine of some of
the uremic patients. The highest sTNFR concentrations were
found in end-stage renal patients. Urine from these patients
when concentrated 20-fold contained as much as 0.15 to 0.24
mg/liter sTNFR-A(p75) and 0.24 to 0.8 mg/liter sTNFR-B(p55).
These remarkably high levels explain the TNFa binding activity
observed in the urine of HD patients and validates their urine as
a good source for these proteins. As in the plasma, the urine
also contained higher levels of sTNFR-B(p55) than of sTNFR-
A(p75).
TNFa plasma concentrations
Plasma levels of TNFa were determined using a T-Cell-
Sciences ELISA kit. In all plasma samples the concentration of
TNFa was less than 10 pg/mI, similar to the values obtained in
normal subjects in agreement with our previous observation
[36].
Discussion
This study shows that two types of soluble TNF receptors are
significantly increased in the plasma of uremic patients. The
results are consistent with the observation of Peetre et a! that
the plasma of HD patients contains high levels of TNFa binding






































0.5 0.7 0.9 1.1
Creatinine, mM/liter
0.5 0.7 0.9 1.1
Creatinine, mM/liter
Fig. 3. Relationship between plasma
concentrations of sTNFRs and urea (A, B) or
creatinine (C, D) in 13 HD patients. Blood
was withdrawn immediately before dialysis
treatment.
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[17, 241. Our present findings are complementary to our previ-
ous observation that the plasma and urine of HD patients
display a TNFa binding activity which interferes with immu-
noassays for TNFa [36].
sTNFR levels were determined in this study using an imniu-
noassay that employs two different and non-cross-reacting
monoclonal antibodies, each specific for a different receptor for
TNFa [39, 40]. Our results show that plasma levels of sTNFRs
are already high in the early stages of renal failure, and increase
further with the development of uremia. Patients treated by HD
over a long period show an additional increase in sTNFRs. Two
distinct mechanisms, which are not necessarily mutually exclu-
sive, could explain these observations: (1.) increased produc-
tion of sTNFRs, and (2.) reduced clearance of sTNFRs due to
renal insufficiency. With regard to the first, human polymor-
phonuclear cells (PMN)s, as well as mononuclear cells, were
shown upon stimulation in vitro to shed TNF receptors, which
could be detected in the medium [24, 43]. Elastase from
azurophilic granules of PMNs was shown in vitro to act on the
75 kDa TNFR, to release a 32 kDa soluble fragment [371. It has
been shown that uremia affects PMNs oxidative metabolism
and phagocytic activity in vitro [44—48]. Oxidative metabolism
of PMNs in the resting state displayed a correlation with
creatinine clearance similar to that found by us for sTNFRs
with creatinine levels [48]. It is possible that reactive oxygen
metabolites may, directly or indirectly, contribute to sTNFR
production in CRF patients. An alternative mechanism that
could account for increased sTNFR levels is the effect of TNF
itself. TNF has been shown to cause an increase in sTNFR
levels in the serum of TNF-treated cancer patients [49].
With regard to the second mechanism, some proteins are
cleared from the plasma by the kidney, where they are filtered,
absorbed by tubular epithelium, and eventually hydrolyzed
within renal cells to their constituent amino acids. As a conse-
quence, when renal function is impaired the plasma half life and
plasma levels of these proteins are markedly elevated [reviewed
in 50]. If sTNFRs are normally cleared from the plasma mainly
through the kidneys, CRF could be expected to lead to the
accumulation of these proteins in the plasma. As the degree of
renal failure increases, smaller amounts of sTNFR would be
cleared by the kidney and more retained in plasma. Such a
mechanism could explain the linear correlation observed here
between plasma sTNFR levels and plasma creatinine, as well as
the additional increase observed in HD patients, when residual
renal function is further reduced. In this case the elevated levels
of sTNFRs would merely be an additional expression of re-
duced renal function. In patients with renal disease, as the
selectivity of the glomerular semi-permeable barrier is altered,
considerable amounts of these proteins may be filtered and
secreted in the urine. This could explain the high concentrations
of sTNFRs found in urine of CRF patients, although shedding
of sTNFRs from damaged renal cells cannot be excluded as a
source of urinary sTNFRs. At the present stage we do not have
sufficient data to differentiate the possibilities we mentioned.
The observation that plasma levels of sTNFRs are consider-
ably higher in long-term HD patients (treated with cuprophane
dialyzers) than in undialyzed ESRD patients, can equally be
explained by extremely low residual renal function, or by
increased receptor production. During a single HD session,
however, no increase of sTNFR levels beyond those account-
able by changes in body weight were observed. After onset of
RD there is no correlation between sTNFRs and creatinine and
urea. This is most probably due to their differential clearance
through the dialysis membrane.
In conclusion, we have demonstrated here that uremia and
dialysis treatment are associated with a considerable increase in
plasma and urinary levels of two soluble TNF receptors. As to
the origin and physiological role of these proteins, their eluci-
dation must await further studies.
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Since the submission of this manuscript, three publications reported
increased plasma levels of sTNFRs in several pathological situations,
including renal failure:
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51:5602—5607, 1991
2. ADOLF GR, APFLER I: A monoclonal antibody-based enzyme im-
munoassay for quantitation of human tumor necrosis factor binding
protein I, a soluble fragment of the 60 kDa TNF receptor, in
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3. LANTZ M, THYSELL H, NILssoN E, OLSSON I: On the binding of
tumor necrosis factor (TNF) to heparin and the release in vivo of the
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